Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Background: Insulin resistance (IR), considered a hallmark of diabetes at the cellular level, is implicated in pre-diabetes, results in type 2 diabetes, and negatively affects mitochondrial function. Diabetes is increasingly associated with enhanced risk of developing Parkinson’s disease (PD); however, the underlying mechanism remains unclear. This study investigated the probable culpability of IR in the pathogenesis of PD. Methods: Using MitoPark mice in vivo models, diabetes was induced by a high-fat diet in the in vivo models, and IR was induced by protracted pulse-stimulation with 100 nM insulin treatment of neuronal cells, in vitro to determine the molecular mechanism(s) underlying altered cellular functions in PD, including mitochondrial dysfunction and α-synuclein (SNCA) aberrant expression. Findings: We observed increased SNCA expression in the dopaminergic (DA) neurons of both the wild-type and diabetic MitoPark mice, coupled with enhanced degeneration of DA neurons in the diabetic MitoPark mice. Ex vivo, in differentiated human DA neurons, IR was associated with increased SNCA and reactive oxygen species (ROS) levels, as well as mitochondrial depolarization. Moreover, we demonstrated concomitant hyperactivation of polo-like kinase-2 (PLK2), and upregulated p-SNCA (Ser129) and proteinase K-resistant SNCA proteins level in IR SH-SY5Y cells, however the inhibition of PLK2 reversed IR-related increases in phosphorylated and total SNCA. Similarly, the overexpression of peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC)-1α suppressed ROS production, repressed PLK2 hyperactivity, and resulted in downregulation of total and Ser129-phosphorylated SNCA in the IR SH-SY5Y cells. Conclusions: These findings demonstrate that IR-associated diabetes promotes the development and progression of PD through PLK2-mediated mitochondrial dysfunction, upregulated ROS production, and enhanced SNCA signaling, suggesting the therapeutic targetability of PLK2 and/or SNCA as potential novel disease-modifying strategies in patients with PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, insulin resistance affects the clearance of Aβ, the hyperphosphorylation of tau, and glucose metabolism and enhances the aberrant expression of α-syn.356,357”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [357]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: A shared comparison of diabetes mellitus and neurodegenerative disorders
Morsi, M., Maher, A., Aboelmagd, O., Johar, D., & Bernstein, L. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26261 · Cited by 49
RetractedDeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611 · cited 1×
“Impaired cellular response to insulin, known as insulin resistance (IR), is a hallmark of type 2 diabetes and contributes to the systemic downstream detrimental effects of diabetes [2].”
BackgroundRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Copps, K. D., & White, M. F. (2012) · Diabetologia · doi:10.1007/s00125-012-2644-8 · Cited by 1,017 · cited 2×
“Mechanistically, since increased p85α expression and IRS1 serine phosphorylation are essential for the induction of clinically-apparent IR [32], we demonstrated significant increase in the p-IRS1/IRS1 ratio (123%, p < 0.”
BackgroundPARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953 · cited 1×
“In addition, deregulated parkin (PRKN) expression and/or activity is pathognomonic to PD, however, parkin-interacting substrate (PARIS/ZNF746), a Krüppel-associated box-zinc finger protein (KRAB-ZFP) that accumulates in models of parkin (PRKN) inactivation and in the brain of patients with PD, has been shown to repres…”
BackgroundQuantitative Analysis of Histological Staining and Fluorescence Using ImageJ
Jensen, E. C. (2013) · The Anatomical Record · doi:10.1002/ar.22641 · Cited by 941
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“Furthermore, several anti-glycemic agents, including exenatide, a glucagon-like peptide analogue, have exerted a disease-modifying effect on PD; exenatide is presently in phase III clinical trial as a neuroprotective drug for patients with PD [18,19].”
BackgroundNeuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Cited by
Items 101–133 of 133
Invernizzi, F., Ciocca, L., Contaldi, E., Inverso, D., Calandrella, D., Mignone, F., Barichella, M., Isaias, I. U., & Pezzoli, G. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1665957 · Cited by 6
Lu, Y., Chen, X., & Lai, Y. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13472-8 · Cited by 3
DYRK1A and Parkinson’s disease, facts and hypotheses
Meijer, L., Lindberg, M. F., Hogrel, G., & Khor, B. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107379 · Cited by 3
The Gut-Brain Axis: A Critical Link between Type 2 Diabetes and Parkinson’s disease
Almohmadi, N. H., Al‐kuraishy, H. M., Hussein, K. S., Turkistani, A., Yousef, F. M., Al-Gareeb, A. I., Abdelaziz, A. M., Elewa, Y. H. A., & Batiha, G. E. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11014-w · Cited by 5
Insulin resistance and neurodegenerative diseases
Prajapati, A. K., Gairola, A., & Mansuri, M. M. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.013 · Cited by 2
Chang, Y., Park, J.-Y., & Song, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-85672-1 · Cited by 2
Ji, W., Wang, C.-J., Wang, X., Qiu, S., & Wang, S.-H. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.09.013 · Cited by 2
Vastrad, B. M., & Vastrad, C. M. (2025) · Genome Instability & Disease · doi:10.1007/s42764-025-00158-8 · Cited by 2
Narcolepsy in Parkinson's disease with insulin resistance
Chunduri, A., Crusio, W. E., & Delprato, A. (2021) · F1000Research · doi:10.12688/f1000research.27413.2 · Cited by 5
Decreased PLK2 promotes atrial fibrillation in diabetic mice through Nrf2/HO-1 pathway
Liu, H.-H., Yang, F., Zhang, L., Zhang, X., Zhao, N., Zhang, Z., Zhou, J., Wei, T.-P., Qian, L., Ding, L., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02480-9 · Cited by 1
Lee, J.-W., Jen, C.-T., Inbaraj, B. S., & Chen, B. (2026) · Antioxidants · doi:10.3390/antiox15020195 · Cited by 2
Mendonça, M. F., Interaminense, A. C., Barros, G. S. T. D. R., Rabelo, L. A., de Oliveira, P. G. G., Sales, R. F., Lyra, A. M. V. D. C., & Silva, H. R. D. S. E. [. (2026) · Neurological Sciences · doi:10.1007/s10072-026-09084-3 · Cited by 3
Aijaz, M., & Ahmad, S. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70131 · Cited by 1
Tung, C.-Y., Lin, Y., Chang, Y.-Y., Ruan, J., Chen, P.-C., Chen, C., Yeh, H., Shen, H., Tsai, H., Li, T.-H., et al. (2026) · Gene · doi:10.1016/j.gene.2026.150292 · Cited by 1
Microalbuminuria as a potential biomarker for Parkinson’s disease severity: A hypothesis
Meléndez‐Flores, J. D., Cavazos-Benítez, A. C., & Estrada-Bellmann, I. E. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110510 · Cited by 1
Ebrahimzadeh, M., Fallahmohammadi, Z., & Akbari, A. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100232 · Cited by 2
Type 2 Diabetes Mellitus and Parkinson's Disease: An Emerging Link
Teli, S., Shalavadi, M. H., Mangannavar, C. V., & Anawal, L. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624334102241115162404 · Cited by 1
Adiposity and Neurological Disorders: A Review
Haboubi, N. Y., Williams, H., & Al-Ansari, A. (2022) · EMJ Neurology · doi:10.33590/emjneurol/21-00177 · Cited by 2
Exploring the link between Parkinson’s disease and Diabetes Mellitus in DrosophilaPreprint
Sanz, F., Solana‐Manrique, C., Lilao‐Garzón, J., Brito‐Casillas, Y., Descalzo, S. M., & Paricio, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.481049 · Cited by 1
Exploration of C-terminal CX3CL1 for reducing age-dependent neurodegeneration
Hudobenko, J., Gayen, M., Benoit, M., Singh, N. K., & Yan, R. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373702
Neuroprotective potential of incretinomimetics
Kokin, A. S., Суплотова, Л. А., Сергеевна, Д. Т., & Makarova, O. B. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-159
Disruption of the dopaminergic system in the pathophysiology of diabetes mellitus
Bykov, Y. V., & Батурин, В. А. (2023) · Ural Medical Journal · doi:10.52420/2071-5943-2023-22-4-119-127
Insulin and neurodegenerative diseases
Ferris, H. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00012-7 · Cited by 1
Eliminating the knowledge gap of overlapped mechanisms of diabetes and neurological disorders
Kadian, M., Vashishth, A., Yadav, A. K., Kaur, S., Joon, P., Banderwal, R., Sharma, G., Dahiya, M., & Kumar, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13195-0.00013-2
Aggarwal, S., Biswas, A., Kharbanda, N., Singh, N., Bisht, K. S., Dey, C., Khatri, S., Tiwari, A., & Maiti, T. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.22.678296
Insulin signaling in confluent diabetes and AD
Abraham, A., Gangadhara, V., & Baliga, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40559-4.00008-8
Noreen, Z., Mondal, T., Johnson, J., Sahota, J., Loffredo, C. A., Nunlee-Bland, G. L., Korba, B. A., Bhatti, A., Chandra, V., & Ghosh, S. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251403462
Ji, W., Wang, C., Wang, X., Liang, Y., Qiu, S., & Wang, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05883-z
Parkinson’s Disease as a Disorder of Spatial–Temporal Symmetry
Park, M. S., & Yoo, H. (2026) · Symmetry · doi:10.3390/sym18050820
Alnsour, L., Al-Samydai, A. M., Sadek, B. S., & Akour, A. A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119614
High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy
Arotçarena, M.-L., Delamarre, A., Cuina, M. L., Martin, H., Balpe, E., Fioramonti, X., Bézard, E., & Meissner, W. G. (2026) · Movement Disorders · doi:10.1002/mds.70424
Ferris, H. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00010-x
Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review
Henriques, J. P., Rahal, J. P. S., Ribeiro, R. D. C. G., Machado, E. B. R., & Negrato, C. A. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70165
Metadata
- Authors
- Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O.
- Affiliations
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University (TW)
- Taipei Medical University Hospital (TW)
- UCL Queen Square Institute of Neurology (GB)
- Corresponding author
- Hong, Chien-Tai
- Bamodu, Oluwaseun
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-03-17
- Volume
- 9
- Issue
- 3
- Pages
- 740
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7140619
- OpenAlex
- W3011296966
- Cited by
- 133
- References
- 55
- Citations by year
- 2026: 14 · 2025: 31 · 2024: 24 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 6
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Taipei Medical University Repository (submittedVersion)
- Funders
- Ministry of Science and Technology, Taiwan (105-2314-B-038-017, 106- 2314-B-038-023 MY3)
- Taipei Medical University (TMU105-AE1-B30)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- insulin resistance, Parkinson's disease, alpha-synuclein, PLK2, mitochondrial dysfunction, reactive oxygen species, dopaminergic neurons, PGC-1α, diabetes mellitus, neurodegeneration
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Male, Mice, Inbred C57BL, Mitochondria, Models, Biological, Parkinson Disease, Phosphoserine, Tyrosine 3-Monooxygenase, Signal Transduction, Genome, Human, Protein Serine-Threonine Kinases, Reactive Oxygen Species, Disease Progression, alpha-Synuclein, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.